MedPath

Sun Pharmaceutical Industries, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://sunpharma.com/usa

Clinical Trials

7

Active:3
Completed:1

Trial Phases

3 Phases

Phase 1:3
Phase 3:1
Not Applicable:3

Drug Approvals

240

FDA:238
CANADA:1

Drug Approvals

Divalproex Sodium

Approval Date
Aug 5, 2025
FDA

Hydrocortisone

Approval Date
May 27, 2025
FDA

Miconazole Nitrate

Approval Date
May 27, 2025
FDA

Deferiprone

Approval Date
May 19, 2025
FDA

Clotrimazole

Approval Date
Apr 23, 2025
FDA

tramadol hydrochloride

Approval Date
Mar 28, 2024
FDA

Methylphenidate Hydrochloride

Approval Date
Mar 27, 2024
FDA

Carvedilol Phosphate

Approval Date
Mar 6, 2024
FDA

Bosentan

Approval Date
Mar 5, 2024
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 24
  • Next

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Not Applicable
3 (42.9%)
Phase 1
3 (42.9%)
Phase 3
1 (14.3%)

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

Not Applicable
Not yet recruiting
Conditions
Actinic Keratosis
Interventions
Drug: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%
Other: Vehicle
Device: Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.
First Posted Date
2025-08-28
Last Posted Date
2025-08-28
Lead Sponsor
Sun Pharmaceutical Industries, Inc.
Target Recruit Count
260
Registration Number
NCT07144852

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

Not Applicable
Not yet recruiting
Conditions
Actinic Keratosis
Interventions
Drug: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%
Other: Vehicle containing excipients only (VEH) without active ingredient
Device: Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E
First Posted Date
2025-08-27
Last Posted Date
2025-08-27
Lead Sponsor
Sun Pharmaceutical Industries, Inc.
Target Recruit Count
160
Registration Number
NCT07144345

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Not Applicable
Recruiting
Conditions
Alopecia Areata
Interventions
First Posted Date
2025-08-21
Last Posted Date
2025-08-21
Lead Sponsor
Sun Pharmaceutical Industries, Inc.
Target Recruit Count
355
Registration Number
NCT07133308
Locations
🇺🇸

Total Skin And Beauty Dermatology Center, Birmingham, Alabama, United States

🇺🇸

Dermatology Research Associates, Los Angeles, California, United States

🇺🇸

Paradigm Clinical Research - San Diego, San Diego, California, United States

and more 19 locations

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Phase 3
Completed
Conditions
Alopecia Areata
Interventions
First Posted Date
2021-09-13
Last Posted Date
2025-06-17
Lead Sponsor
Sun Pharmaceutical Industries, Inc.
Target Recruit Count
407
Registration Number
NCT05041803
Locations
🇫🇷

Service de Dermatologie CHRU de Brest - Hopital Morvan, Brest Cedex, Finistere, France

🇫🇷

Service de Dermatologie Centre Hospitalier Universitaire de Nice - Hopital Archet 2, Nice, Provence-Alpes-Cote d'Azur, France

🇫🇷

CHU de Bordeaux, Hopital Saint-Andre, Bordeaux, France

and more 36 locations

News

Sun Pharma Discontinues Psoriasis and Eczema Drug SCD-044 After Phase 2 Trial Failures

Sun Pharma's experimental oral drug SCD-044 (Vibozilimod) failed to meet primary endpoints in Phase 2 trials for both psoriasis and atopic dermatitis, missing the 75% improvement target in PASI and EASI scores at 16 weeks.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.